Generic Name and Formulations:
Methoxy polyethylene glycol-epoetin beta 30mcg/0.3mL, 50mcg/0.3mL, 75mcg/0.3mL, 100mcg/0.3mL, 120mcg/0.3mL, 150mcg/0.3mL, 200mcg/0.3mL, 250mcg/0.3mL; 360mcg/0.6mL; soln for SC or IV inj; preservative-free.
Vifor Pharma Group
Indications for MIRCERA:
Treatment of anemia associated with chronic kidney disease (CKD) in adults on or not on dialysis and in pediatric patients on hemodialysis who are converting from another erythropoietin-stimulating agent (ESA) after their hemoglobin level was stabilized with an ESA.
Limitations Of use:
Not recommended to treat anemia due to cancer chemotherapy. Not a substitute for red blood cell (RBC) transfusions in patients who require immediate anemia correction. Not shown to improve symptoms, physical functioning, or health-related quality of life.
See full labeling. Individualize. Do not increase dose sooner than once every 4 weeks. Avoid frequent dose adjustments. Give as SC (abdomen, arm, or thigh) or IV inj. >17yrs: Dialysis (hemoglobin <10g/dL): initially 0.6mcg/kg as a single injection once every 2 weeks; interrupt or reduce dose if hemoglobin approaches or exceeds 11g/dL. Once stabilized, double the dose and give once monthly. Non-dialysis (hemoglobin <10g/dL, RBC transfusion likely + reduced risk of alloimmunization and/or transfusion-related goals): initially 0.6mcg/kg as a single injection once every 2 weeks; interrupt or reduce dose if hemoglobin >10g/dL. Once stabilized, double the dose and give once monthly. Reduce dose by ≥25% if hemoglobin rises >1g/dL in any 2-week period. Increase dose by 25% if inadequate response (<1g/dL increase) after 4 weeks; discontinue if response not improved after a 12-week escalation period. Conversion from epoetin alfa or darbepoetin alfa: see full labeling.
See full labeling. Individualize. Do not increase dose sooner than once every 4 weeks. Avoid frequent dose adjustments. Give as IV inj once every 4 weeks. <5yrs: not established. 5–17yrs: Conversion from epoetin alfa: 4 x previous weekly epoetin alfa dose (Units)/125. Conversion from darbepoetin alfa: 4 x previous weekly darbepoetin alfa dose (mcg)/0.55. Reduce dose by ≥25% if hemoglobin rises >1g/dL in any 2-week period. Increase dose by 25% if inadequate response (<1g/dL increase) after 4 weeks; discontinue if response not improved after a 12-week escalation period.
Uncontrolled hypertension. Pure red cell aplasia (PRCA) occurring after Mircera treatment or other erythropoetin protein drugs.
ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access, and tumor progression or recurrence.
Increased risk of mortality, myocardial infarction, stroke, thromboembolism with higher hemoglobin targets (>11g/dL). Coexisting cardiovascular disease and stroke. Increased risk of mortality and/or risk of tumor progression or recurrence in cancer patients. Control hypertension prior to and during treatment; reduce or withhold dose if BP becomes uncontrolled. Evaluate iron status prior to and during treatment; give supplemental iron if serum ferritin <100mcg/L or transferrin saturation <20%. Correct or exclude other causes of anemia prior to initiation. Monitor hemoglobin weekly until stable, then at least monthly. Use lowest effective dose to reduce the need for RBC transfusions. Monitor for premonitory neurologic symptoms during first several months. Withhold dose and evaluate for neutralizing antibodies if severe anemia and low reticulocyte count develop; permanently discontinue if PRCA occurs. Permanently discontinue if serious allergic/anaphylactic reaction or severe cutaneous reaction (eg, SJS/TEN) occurs. Pregnancy. Nursing mothers.
Erythropoiesis stimulating protein.
May require increased anticoagulation (heparin) during hemodialysis.
Hypertension, diarrhea, nasopharyngitis; seizures, thromboembolism, PRCA, serious allergic reactions, severe cutaneous reactions.
Single-dose prefilled syringe—1 (w. supplies)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Distinct Characteristics in Children at Risk for Schizophrenia vs Bipolar Disorder
- Nonstimulants May Be an Appropriate Alternative to Stimulants for Treating ADHD
- Psychotic Experiences Associated With Increased Risk for Eating Disorders in Adolescents
- Novel Parent-Child Interaction Therapy Targets Preschool-Aged Depression
- Remission of Treatment-Resistant Depression in Veterans Depends on Close Clinical Observation
- Medical Clearance of Psych Patients in the ED: Consensus Recommendations
- From Abused Child to Serial Killer: Investigating Nature vs Nurture in Methods of Murder
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Effect of Long-Term Lisdexamfetamine Dimesylate for Major Depressive Disorder
- 5-Factor Brief Negative Symptom Scale Validation in Schizophrenia
- Do the Deceased Have Rights to Autonomy? An Ethical Examination of Posthumous Conception
- Mothers' Healthy Lifestyle Tied to Drop in Offspring Obesity
- Parental Incarceration Linked to Unhealthy Behaviors in Teens